Quantcast
Home > Quotes > CORT
CORT

Corcept Therapeutics Incorporated Common Stock (CORT) Quote & Summary Data

$16.11
*  
1.08
6.28%
Get CORT Alerts
*Delayed - data as of Dec. 14, 2018  -  Find a broker to begin trading CORT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
22
Today's High / Low
$ 17.31 / $ 15.475
Share Volume
2,835,612
50 Day Avg. Daily Volume
1,420,177
Previous Close
$ 17.19
52 Week High / Low
$ 25.96 / $ 11.21
Market Cap
1,860,250,666
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.1

Intraday Chart

Shares Traded

Share Volume:
2,835,612
50 Day Avg. Daily Volume:
1,420,177

P/E Ratio

P/E Ratio:
13.54
Forward P/E (1y):
28.65
Earnings Per Share (EPS):
$ 1.19

Trading Range

The current last sale of $16.11 is 43.71% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 17.31 $ 25.96
 Low: $ 15.475 $ 11.21

ETFs with CORT as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
36% Barron's 400 (BFOR) -6.85 (-15.41%)
3.43% Invesco Dynamic Pharmaceuticals ETF (PJP) -3.11 (-4.45%)
0.26% GS ActiveBeta U.S. Small Cap Equity ETF (GSSC) -6.92 (-14.37%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Elevated levels and abnormal release patterns of cortisol are implicated in a broad range of diseases. Since our founding in 1998, we have developed mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor ("GR"). We have discovered three structurally distinct series of proprietary, selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor ("PR") and so do not cause effects associated with antagonism of progesterone activity. Pre-clinical and clinical development of compounds from these series are in progress.  ... More ...  


Risk Grade

Where does CORT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 16.98
Open Date:
Dec. 14, 2018
Close Price:
$ 16.11
Close Date:
Dec. 14, 2018

Consensus Recommendation

Analyst Info